Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have earned a consensus rating of “Moderate Buy” from the twenty-seven research firms that are presently covering the stock, MarketBeat.com reports. Nine research analysts have rated the stock with a hold recommendation, seventeen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $787.8750.

A number of research firms recently weighed in on REGN. Guggenheim upped their price target on Regeneron Pharmaceuticals from $995.00 to $1,000.00 and gave the stock a “buy” rating in a report on Tuesday. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a report on Monday, May 18th. BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Cantor Fitzgerald lowered their target price on Regeneron Pharmaceuticals from $785.00 to $750.00 and set an “overweight” rating on the stock in a report on Monday, July 6th. Finally, Sanford C. Bernstein dropped their price target on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research report on Wednesday, April 8th.

Regeneron Pharmaceuticals Stock Up 0.5%

REGN stock opened at $675.19 on Friday. The company has a market cap of $71.38 billion, a P/E ratio of 16.45, a P/E/G ratio of 1.49 and a beta of 0.24. Regeneron Pharmaceuticals has a 52 week low of $541.00 and a 52 week high of $821.11. The company’s 50-day moving average price is $639.22 and its 200 day moving average price is $716.58. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same period in the prior year, the business posted $8.22 earnings per share. The firm’s revenue for the quarter was up 19.0% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals will post 37.12 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Guggenheim raised its price target on Regeneron to $1,000 from $995 and reiterated a buy rating, signaling continued analyst confidence in the company’s longer-term outlook.
• Neutral Sentiment: Regeneron said it completed a mid-stage study for REGN7544 in POTS, which could be relevant for its pipeline, but the market impact is unclear from the update alone.
• Negative Sentiment: Multiple law firms announced or reminded investors about a pending class action lawsuit against Regeneron related to disclosures around a Phase 3 melanoma study failure, reinforcing legal and reputational risk for the stock.
• Negative Sentiment: The lawsuit filings and deadline reminders suggest the company faces ongoing litigation risk and potential distraction as investors focus on trial disclosure concerns rather than near-term fundamentals.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the transaction, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wedge Capital Management L L P NC raised its holdings in shares of Regeneron Pharmaceuticals by 20.3% in the second quarter. Wedge Capital Management L L P NC now owns 47,775 shares of the biopharmaceutical company’s stock worth $29,790,000 after acquiring an additional 8,063 shares during the last quarter. Insight Wealth Strategies LLC boosted its stake in shares of Regeneron Pharmaceuticals by 26.9% during the second quarter. Insight Wealth Strategies LLC now owns 8,734 shares of the biopharmaceutical company’s stock valued at $5,456,000 after acquiring an additional 1,850 shares during the last quarter. Tema ETFs LLC increased its position in Regeneron Pharmaceuticals by 2.3% during the 2nd quarter. Tema ETFs LLC now owns 5,481 shares of the biopharmaceutical company’s stock worth $3,418,000 after purchasing an additional 121 shares in the last quarter. E. Ohman J or Asset Management AB increased its position in Regeneron Pharmaceuticals by 35.2% during the 2nd quarter. E. Ohman J or Asset Management AB now owns 3,840 shares of the biopharmaceutical company’s stock worth $2,394,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Harrell Investment Partners LLC raised its stake in Regeneron Pharmaceuticals by 1.3% in the 2nd quarter. Harrell Investment Partners LLC now owns 2,089 shares of the biopharmaceutical company’s stock valued at $1,303,000 after purchasing an additional 27 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.